Stock market today: S&P 500 rides Apple-led tech rally to close higher
GARDEN CITY, N.Y. - Beyond Air, Inc. (NASDAQ:XAIR), a medical device company with a market capitalization of $15.4 million and impressive revenue growth of 220% over the last twelve months, has been awarded a national group purchasing agreement with Premier, Inc. for its LungFit PH system and disposable NO2 Smart Filters, effective July 15, according to a company press release. InvestingPro analysis suggests the stock is currently undervalued based on its Fair Value model.
The agreement allows Premier’s network of U.S. hospitals and healthcare providers to access special pricing and terms for Beyond Air’s cylinder-free nitric oxide delivery system. With a strong current ratio of 3.2, the company maintains healthy liquidity to support its commercial expansion.
The LungFit PH system uses patented Ionizer technology to generate nitric oxide (NO) from ambient air on demand, delivering it directly to ventilator circuits. The system operates on power equivalent to a 60-watt lightbulb and includes Smart Filters that remove nitrogen dioxide byproducts to ensure safe delivery to patients.
"We are proud to have been awarded this agreement with Premier, expanding access to our LungFit PH system across their extensive network," said Steve Lisi, Chairman and CEO of Beyond Air.
The system is designed to deliver nitric oxide doses ranging from 0.5 ppm to 80 ppm for ventilated patients with persistent pulmonary hypertension of the newborn (PPHN). Each Smart Filter provides 12 hours of therapy regardless of ventilator demands.
Premier is a healthcare improvement company serving approximately two-thirds of U.S. healthcare providers. The contract was negotiated with support from Beyond Air’s strategic partner, HealthCare Links.
The LungFit PH system has received regulatory approval in the United States, European Union, Australia, Thailand, Saudi Arabia, Taiwan, and New Zealand.
In other recent news, Beyond Air reported its fourth-quarter 2025 earnings, revealing a better-than-expected performance in earnings per share (EPS), although revenue fell short of forecasts. The company posted an EPS of -$0.09, surpassing the anticipated -$0.15, which marked a 40% positive surprise. However, revenue came in at $1.15 million, below the expected $1.38 million, resulting in a 16.67% negative surprise. Additionally, Beyond Air announced a 1-for-20 reverse stock split, effective July 14, 2025, following approval from shareholders during a special meeting. This move allows the board to consolidate every 10 to 50 shares into one, with the exact ratio at their discretion. In related developments, D. Boral Capital initiated coverage on Beyond Air with a Buy rating, citing the company’s LungFit platform as a significant advancement in nitric oxide delivery. The platform generates the gas on demand from ambient air, eliminating the need for high-pressure cylinders or chemical cassettes. These recent developments reflect strategic initiatives and investor interest in Beyond Air’s innovations and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.